David J. Arthur - 26 May 2022 Form 4 Insider Report for Salarius Pharmaceuticals, Inc. (SLRX)

Role
Chief Executive Officer, Director
Signature
/s/Mark Rosenblum, as Attorney-in-Fact
Issuer symbol
SLRX
Transactions as of
26 May 2022
Net transactions value
+$7,985
Form type
4
Filing time
31 May 2022, 17:17:24 UTC
Previous filing
05 May 2022
Next filing
08 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLRX Common Stock Purchase $612 +3,400 +1.3% $0.1800 263,074 26 May 2022 Direct
transaction SLRX Common Stock Purchase $3,385 +18,600 +7.1% $0.1820 281,674 26 May 2022 Direct
transaction SLRX Common Stock Purchase $127 +708 +0.25% $0.1800 282,382 26 May 2022 By son F1
transaction SLRX Common Stock Purchase $1,870 +10,392 +3.7% $0.1799 292,774 26 May 2022 By son F1
transaction SLRX Common Stock Purchase $1,990 +10,800 +3.7% $0.1843 303,574 26 May 2022 By daughter F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.